Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
18.95
+0.47 (2.54%)
At close: Sep 5, 2025, 4:00 PM
18.96
+0.01 (0.05%)
After-hours: Sep 5, 2025, 7:58 PM EDT
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.18B in the quarter ending June 30, 2025, with 0.29% growth. This brings the company's revenue in the last twelve months to $16.63B, up 2.07% year-over-year. In the year 2024, Teva Pharmaceutical had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.63B
Revenue Growth
+2.07%
P/S Ratio
1.30
Revenue / Employee
$451,480
Employees
36,830
Market Cap
21.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TEVA News
- 1 day ago - Colorado must face Teva's lawsuit over free allergy pen law - Reuters
- 4 days ago - Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September - GlobeNewsWire
- 9 days ago - US FDA approves Teva Pharmaceuticals' generic obesity drug - Reuters
- 9 days ago - Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue - Seeking Alpha
- 18 days ago - Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth” - Business Wire
- 4 weeks ago - US FDA approves Teva's Ajovy for migraine prevention in children - Reuters
- 5 weeks ago - Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside - Seeking Alpha
- 5 weeks ago - Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript - Seeking Alpha